Health and Healthcare
Can Sage Therapeutics Press Even Further With Its Depression Trial?
Published:
Last Updated:
Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw a handy gain on Monday after the company announced a successful mid-stage trial for the treatment of major depressive disorder (MDD). Specifically the company reported encouraging top-line results for SAGE-217, which met the primary endpoint of safety and tolerability.
The trial also examined the effect of SAGE-217 on the Hamilton Rating Scale for Depression (HAM-D) total score, in addition to other secondary measures. Patients in the trial had a mean HAM-D total score of 27.2 at baseline. Data demonstrated a mean reduction from baseline in the HAM-D of 19.9 points at Day 15, with 85% (11 of 13) patients showing at least a 50% reduction of their HAM-D and 62% (8 of 13) of patients achieving remission, as determined by a HAM-D score of 7 or less.
The positive results from this clinical trial, along with the outcomes observed with SAGE-547 in postpartum depression, further validate studying this mechanism as a potential broad therapy for the treatment of mood disorders.
The primary endpoint for the Part A study was to evaluate the safety and tolerability of SAGE-217. The Part B phase of the trial will be a randomized, double-blind, parallel-group, placebo-controlled study evaluating SAGE-217 as a treatment for MDD.
Jeff Jonas, M.D., CEO of Sage, commented:
Understanding the caveats associated with open-label data, we are highly encouraged by the strong signal we achieved in this study, which met our internal criteria for achieving a positive signal and thus supported our plan to proceed to the double-blind, placebo-controlled part of the Phase 2 trial. These initial results in MDD were achieved utilizing our data-driven approach to CNS drug development – employing efficient human proof-of-concept studies to both uncover activity signals and help understand future trial methodology, before investing in larger clinical programs.
Shares of Sage were trading up 13% at $53.57 on Monday, with a consensus analyst price target of $75.27 and a 52-week trading range of $26.28 to $56.45.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
